Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Interethnic variability of ERCC2 polymorphisms

Abstract

Excision Repair Cross-Complementing Rodent Repair Group 2 (ERCC2) plays an important role in DNA repair by eliminating bulky DNA adducts produced by platinum agents during the nucleotide excision repair pathway. Several studies have associated polymorphisms in ERCC2 with response to platinum therapy, lung cancer risk, and DNA repair capacity. This study examined ERCC2 polymorphisms and haplotype structure across 18.9 kb in 95 European, 95 African, and 95 Asian individuals. Single-nucleotide polymorphisms (SNPs) (ERCC2 −9164 A>T, −1989 A>G, −516 G>A, 468 C>A [Arg156Arg], 1737 C>T [Val579Val], 2133 C>T [Asp711Asp], and 2251 T>G [Lys751Gln]) were mined and mapped using Golden Path, PolyMAPr, and Promolign. Genotyping was performed using PCR and pyrosequencing. Allele frequencies ranged from 0 to 0.47 (Europeans), 0.05 to 0.72 (Africans), and 0 to 0.47 (Asians). The synonymous cSNP at codon 579 could not be confirmed in our populations. There were significant differences in haplotype structure and frequency between populations. This information on ERCC2 genomic structure will allow the construction of definitive studies to clarify the clinical role of this important gene.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Lamerdin JE, Stilwagen SA, Ramirez MH, Stubbs L, Carrano AV . Sequence analysis of the ERCC2 gene regions in human, mouse, and hamster reveals three linked genes. Genomics 1996; 34: 399–409.

    Article  CAS  PubMed  Google Scholar 

  2. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ . A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61: 8654–8658.

    CAS  PubMed  Google Scholar 

  3. Liang G, Xing D, Miao X, Tan W, Yu C, Lu W et al. Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population. Int J Cancer 2003; 105: 669–673.

    Article  CAS  PubMed  Google Scholar 

  4. de Laat WL, Jaspers NG, Hoeijmakers JH . Molecular mechanism of nucleotide excision repair. Genes Dev 1999; 13: 768–785.

    Article  CAS  PubMed  Google Scholar 

  5. Watters JW, McLeod HL . Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta 2003; 1603: 99–111.

    CAS  PubMed  Google Scholar 

  6. Drapkin R, Reardon JT, Ansari A, Huang JC, Zawel L, Ahn K et al. Dual role of TFIIH in DNA excision repair and in transcription by RNA polymerase II. Nature 1994; 368: 769–772.

    Article  CAS  PubMed  Google Scholar 

  7. Seker H, Butkiewicz D, Bowman ED, Rusin M, Hedayati M, Grossman L et al. Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. Cancer Res 2001; 61: 7430–7434.

    CAS  PubMed  Google Scholar 

  8. Frederick GD, Amirkhan RH, Schultz RA, Friedberg EC . Structural and mutational analysis of the Xeroderma pigmentosum group D (XPD) gene. Hum Mol Genet 1994; 3: 1783–1788.

    Article  CAS  PubMed  Google Scholar 

  9. Broughton BC, Steingrimsdottir H, Weber CA, Lehmann AR . Mutations in the Xeroderma pigmentosum group D DNA repair/transcription gene in patients with trichothiodystrophy. Nat Genet 1994; 7: 189–194.

    Article  CAS  PubMed  Google Scholar 

  10. Bootsma D, Hoeijmakers JH . The molecular basis of nucleotide excision repair syndromes. Mutat Res 1994; 307: 15–23.

    Article  CAS  PubMed  Google Scholar 

  11. Misra RR, Ratnasinghe D, Tangrea JA, Virtamo J, Andersen MR, Barrett M et al. Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE/ref-1, and the risk of lung cancer among male smokers in Finland. Cancer Lett 2003; 191: 171–178.

    Article  CAS  PubMed  Google Scholar 

  12. Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001; 61: 1354–1357.

    CAS  PubMed  Google Scholar 

  13. Johnson NP, Hoeschele JD, Rahn RO, O'Neill JP, Hsie AW . Mutagenicity, cytotoxicity, and DNA binding of platinum(II)-chloroamines in Chinese hamster ovary cells. Cancer Res 1980; 40: 1463–1468.

    CAS  PubMed  Google Scholar 

  14. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23–30.

    Article  CAS  PubMed  Google Scholar 

  15. Goldberg R . Oxaliplatin in colorectal cancer: current studies. Oncology 2000; 14: 42–47.

    CAS  PubMed  Google Scholar 

  16. Weinshilboum R, Wang L . Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity. Clin Pharmacol Ther 2004; 75: 253–258.

    Article  CAS  PubMed  Google Scholar 

  17. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12: 121–132.

    Article  CAS  PubMed  Google Scholar 

  18. Uno Y, Sakamoto Y, Yoshida K, Hasegawa T, Hasegawa Y, Koshino T et al. Characterization of six base pair deletion in the putative HNF1-binding site of human PXR promoter. J Hum Genet 2003; 48: 594–597.

    Article  CAS  PubMed  Google Scholar 

  19. Freimuth RR, Stormo GD, McLeod HL . PolyMAPr: programs for polymorphism database mining, annotation, and functional analysis. Hum Mutat, in press.

  20. Zhao T, Chang L-W, McLeod HL, Stormo GD . PromoLign: A database for upstream region analysis and SNPs. Hum Mutat 2004; 23: 534–539.

    Article  CAS  PubMed  Google Scholar 

  21. McLeod HL, Syvanen AC, Githang'a J, Indalo A, Ismail D, Dewar K et al. Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals. Pharmacogenetics 1998; 8: 195–199.

    CAS  PubMed  Google Scholar 

  22. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL . Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999; 8: 367–370.

    Article  CAS  PubMed  Google Scholar 

  23. Rose CM, Marsh S, Ameyaw MM, McLeod HL . Pharmacogenetic analysis of clinically relevant genetic polymorphisms. Methods Mol Med 2003; 85: 225–237.

    CAS  PubMed  Google Scholar 

  24. Incorporation AB . Relative quantification of gene expression. User Bulletin No. 2 1997.

  25. Pfaffl MW . A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Yu J, Marsh S, Ahluwalia R, McLeod HL . Ferredoxin reductase: pharmacogenomic assessment in colorectal cancer. Cancer Res 2003; 63: 6170–6173.

    CAS  PubMed  Google Scholar 

  27. Schaid DJ, McDonnell SK, Wang L, Cunningham JM, Thibodeau SN . Caution on pedigree haplotype inference with software that assumes linkage equilibrium. Am J Hum Genet 2002; 71: 992–995.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Ke X, Cardon LR . Efficient selective screening of haplotype tag SNPs. Bioinformatics 2003; 19: 287–288.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the NIH Pharmacogenetics Research Network (GM63340; http://pharmacogenetics.wustl.edu) and the Siteman Cancer Center (P30CA091842). These data have been deposited in the Pharmacogenetics Knowledge Base (http://www.pharmgkb.org/).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S Marsh.

Additional information

SUPPLEMENTARY INFORMATION

Supplementary Information accompanies the paper on TPJ website http://www.nature.com/tpj).

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

King, C., Yu, J., Freimuth, R. et al. Interethnic variability of ERCC2 polymorphisms. Pharmacogenomics J 5, 54–59 (2005). https://doi.org/10.1038/sj.tpj.6500283

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500283

Keywords

This article is cited by

Search

Quick links